Table 1

Selected major studies of post-TAVR readmission

StudySample sizeFollow-up
duration
Readmission
rate (%)
Specific readmission predictors identified
Khera et al 10 39 30530 days16.2Anaemia.
Acute kidney injury.
Chronic kidney disease.
Chronic lung disease.
Chronic liver disease.
Atrial fibrillation.
Discharge disposition.
Index admission ≥5 days.
Ando et al 43 46 79430 days14.5n/a
Sanchez et al 20 10 34530 days9.2Diabetes.
Chronic kidney disease (Cr >1.6).
Atrial fibrillation.
Index admission ≥5 days.
Vascular complication.
Advanced heart failure.
Home oxygen.
Decreased 5 m gait speed.
≥Moderate aortic or mitral regurgitation.
Danielsen et al 12 Meta-analysis of 20 studies30 days16Non-transfemoral TAVR.
>1 admission in year pre-TAVR.
Diabetes.
Chronic kidney disease.
Chronic lung disease.
Atrial fibrillation.
Major bleeding.
Index admission >7 days.
Kolte et al 16 12 22130 days17.9
(61.8 non-cardiac)
Transapical TAVR.
Acute kidney injury.
Chronic kidney disease.
Chronic lung disease.
Elixhauser comorbidities.
Discharge to nursing facility.
Index admission >5 days.
Vejpongsa et al 15 490230 days17.2 (65.2 non-cardiac) Female sex.
 Transapical TAVR.
 Congestive heart failure.
 Chronic obstructive pulmonary disease.
 Non-teaching hospital.
Arai et al 4 121530 days3.5Acute kidney injury.
1 year18.4 (65.5 non-cardiac)Anaemia.
Hypoalbuminaemia.
Atrial fibrillation.
≥Moderate aortic regurgitation.
Nombela-Franco et al 17 72030 days14.6 Anaemia.
 Low LVEF.
 Antiplatelet+anticoagulation therapy at discharge.
 Major bleeding.
1 year43.9 (59 non-cardiac) Chronic kidney disease.
 Chronic obstructive pulmonary disease.
 Peripheral vascular disease.
 Atrial fibrillation.
Holmes et al 2 12 18230 days17.4n/a
1 year53.2Female sex.
Non-transfemoral TAVR.
Moderate or severe lung disease.
Renal failure.
Low LVEF.
Increased STS PROM score.
Franzone et al 23 8681 year25.4 (53.9 non-cardiac)Male sex.
Chronic kidney disease.
Previous myocardial infarction.
Atrial fibrillation.
Major bleeding.
  • Cr, creatinine (mg/dL); LVEF, left ventricular ejection fraction; STS PROM, Society of Thoracic Surgeons Predicted Risk of Mortality; TAVR, transcatheter aortic valve replacement.